Drugs / SETOGEPRAM
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05349435 | May → Jun 2022 | urea cycle disorder or inherited hyperammonemia | Liminal BioSciences Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04695041 | Dec 2020 → Oct 2021 | — | Liminal BioSciences Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03637049 | Jul → Aug 2018 | — | Liminal BioSciences Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02955888 | Jan 2017 → Feb 2018 | cystic fibrosis | Liminal BioSciences Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02739217 | Feb 2016 → Sep 2017 | diabetes mellitus | Liminal BioSciences Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02538536 | Jul 2015 → Jan 2017 | idiopathic pulmonary fibrosis | Liminal BioSciences Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02562573 | May 2015 → Nov 2016 | metabolic syndrome X, type 2 diabetes mellitus | Liminal BioSciences Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03184584 | Oct 2017 → May 2020 | Alstrom syndrome | Liminal BioSciences Ltd. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03081598 Comparator | May 2017 → Sep 2018 | metabolic syndrome X, type 2 diabetes mellitus | Liminal BioSciences Ltd. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SETOGEPRAM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297635 ↗ |
| Known as | Fezagepras | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05349435 ↗ |
| Known as | PBI-4050 | “This is a Phase 2, multi-center, double blind, placebo controlled study to evaluate the safety and tolerability of PBI-4050, and its effects on the pancreatic, pulmonary...” NCT02955888 ↗9“The purpose of this study is to compare the safety, tolerability and pharmacokinetic profile of fezagepras (PBI-4050) to that of sodium phenylbutyrate (PBA) when both products...” NCT05349435 ↗ |
| Action | Activate | “Free fatty acid receptor 1 agonist” CHEMBL4297635 ↗ |
| Action | Inhibit | “G-protein coupled receptor 84 antagonist” CHEMBL4297635 ↗ |
| Modality | Small molecule | — CHEMBL4297635 ↗ |
| Route | Oral | “administered orally” NCT02538536 ↗ |
| Target | FFAR1 | “Free fatty acid receptor 1 agonist” CHEMBL4297635 ↗ |
| Target | GPR84 | “G-protein coupled receptor 84 antagonist” CHEMBL4297635 ↗ |